eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 1.5%

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) shares traded up 1.5% during mid-day trading on Wednesday . The company traded as high as $2.13 and last traded at $2.08. 118,184 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 307,054 shares. The stock had previously closed at $2.05.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of eFFECTOR Therapeutics in a research note on Thursday, March 28th.

eFFECTOR Therapeutics Stock Up 1.5 %

The firm has a 50 day moving average price of $7.88 and a 200 day moving average price of $10.74. The stock has a market cap of $7.68 million, a PE ratio of -0.12 and a beta of 0.94.

eFFECTOR Therapeutics (NASDAQ:EFTR) last released its quarterly earnings results on Monday, March 25th. The company reported ($3.42) EPS for the quarter, missing the consensus estimate of ($2.73) by ($0.69). Equities analysts forecast that eFFECTOR Therapeutics, Inc. will post -5.18 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in eFFECTOR Therapeutics stock. Sonora Investment Management Group LLC purchased a new stake in shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 125,000 shares of the company’s stock, valued at approximately $75,000. Sonora Investment Management Group LLC owned about 0.29% of eFFECTOR Therapeutics as of its most recent filing with the SEC. Institutional investors own 57.67% of the company’s stock.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.